NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00024-0656-01 | 00024-0656 | Isatuximab | Sarclisa | 500.0 mg/25mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Mar 2, 2020 | In Use | |
70771-1678-07 | 70771-1678 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
74527-0022-03 | 74527-0022 | margetuximab-cmkb | MARGENZA | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 15, 2021 | In Use | |
57894-0111-02 | 57894-0111 | ciltacabtagene autoleucel | CARVYKTI | 100000000.0 1/1 | Immunotherapy | CAR-T | BCMA | Intravenous | Feb 28, 2022 | In Use | |
00173-0821-33 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
55513-0078-01 | 55513-0078 | Talimogene Laherparepvec | Imlygic | 1000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
00085-0539-01 | 00085-0539 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Jul 31, 2016 | No Longer Used | ||
63304-0042-01 | 63304-0042 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
59572-0420-21 | 59572-0420 | Lenalidomide | Revlimid | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 10, 2013 | In Use | |
45802-0076-00 | 45802-0076 | Imiquimod | Imiquimod | 50.0 mg/1000mg | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Apr 20, 2010 | Aug 1, 2013 | No Longer Used |
31722-0258-28 | 31722-0258 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
50242-0105-01 | 50242-0105 | polatuzumab vedotin | POLIVY | 140.0 mg/7.52mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Jun 10, 2019 | In Use | |
62856-0603-01 | 62856-0603 | Denileukin diftitox | Ontak | 150.0 ug/mL | Immunotherapy | Cytokine | Interleukin-2 | Intravenous | Nov 1, 2013 | Nov 1, 2013 | No Longer Used |
64116-0011-01 | 64116-0011 | Interferon gamma-1b | Actimmune | Immunotherapy | Cytokine | Interferon | Feb 25, 1999 | Mar 31, 2015 | No Longer Used | ||
59572-0775-01 | 59572-0775 | Luspatercept | Reblozyl | 75.0 mg/1 | Immunotherapy | Erythropoiesis-Stimulating Agent | Subcutaneous | Nov 8, 2019 | In Use | ||
55513-0077-01 | 55513-0077 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 10.0 mg/14ml | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | Jun 12, 2024 | In Use | |
00173-0808-05 | 00173-0808 | Ofatumumab | Arzerra | Immunotherapy | Monoclonal Antibody | CD20 | Oct 26, 2009 | Mar 31, 2012 | No Longer Used | ||
50881-0006-03 | 50881-0006 | Retifanlimab-dlwr | ZYNYZ | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 22, 2023 | In Use | |
76282-0699-47 | 76282-0699 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
70710-1033-08 | 70710-1033 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
55513-0955-01 | 55513-0955 | Panitumumab | Vectibix | 200.0 mg/10mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | Feb 28, 2010 | No Longer Used |
70710-1031-07 | 70710-1031 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
00173-0821-01 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
63304-0042-27 | 63304-0042 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
69448-0016-11 | 69448-0016 | Trastuzumab-strf | HERCESSI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use |
Found 11398 results — Export these results